Shannon Thyme Klinger is Chief Legal Officer of Moderna, Inc.. Currently has a direct ownership of 25,612 shares of MRNA, which is worth approximately $896,676. The most recent transaction as insider was on Mar 02, 2023, when has been sold 459 shares (Common Stock) at a price of $136.43 per share, resulting in proceeds of $62,621. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 25.6K
25.27% 3M change
176.38% 12M change
Total Value Held $896,676

Shannon Thyme Klinger Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 02 2023
SELL
Open market or private sale
$62,621 $136.43 p/Share
459 Reduced 8.05%
5,243 Common Stock
Mar 01 2023
BUY
Exercise of conversion of derivative security
-
930 Added 14.02%
5,702 Common Stock
Dec 08 2022
SELL
Open market or private sale
$87,783 $179.15 p/Share
490 Reduced 9.31%
4,772 Common Stock
Dec 07 2022
BUY
Exercise of conversion of derivative security
-
1,139 Added 17.79%
5,262 Common Stock
Sep 08 2022
SELL
Open market or private sale
$65,696 $137.44 p/Share
478 Reduced 10.8%
3,949 Common Stock
Sep 07 2022
BUY
Exercise of conversion of derivative security
-
1,138 Added 20.45%
4,427 Common Stock
Jun 08 2022
SELL
Open market or private sale
$187,372 $148.12 p/Share
1,265 Reduced 27.78%
3,289 Common Stock
Jun 07 2022
BUY
Exercise of conversion of derivative security
$637,560 $140.0 p/Share
4,554 Added 50.0%
4,554 Common Stock

Also insider at

RFL
Rafael Holdings, Inc. Real Estate
STK

Shannon Thyme Klinger

Chief Legal Officer
Cambridge, MA

Track Institutional and Insider Activities on MRNA

Follow Moderna, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MRNA shares.

Notify only if

Insider Trading

Get notified when an Moderna, Inc. insider buys or sells MRNA shares.

Notify only if

News

Receive news related to Moderna, Inc.

Track Activities on MRNA